Last $12.10 USD
Change Today +0.25 / 2.11%
Volume 223.8K
ELOS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 3:04 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

syneron medical ltd (ELOS) Snapshot

Open
$12.18
Previous Close
$11.85
Day High
$12.20
Day Low
$11.87
52 Week High
04/2/14 - $12.88
52 Week Low
10/15/14 - $8.32
Market Cap
427.5M
Average Volume 10 Days
485.2K
EPS TTM
$-0.05
Shares Outstanding
35.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNERON MEDICAL LTD (ELOS)

syneron medical ltd (ELOS) Related Businessweek News

No Related Businessweek News Found

syneron medical ltd (ELOS) Details

Syneron Medical Ltd., together with its subsidiaries, engages in the research, manufacture, development, marketing, and sale of aesthetic medical products worldwide. The company develops products based on its proprietary Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy and optical energy to provide aesthetic medical treatments. Its products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, laser-assisted lipolysis, and topical skin brightening products. It also develops, manufactures, and markets non-invasive technologies for fat cell destruction and body sculpting; and Viador system, a handheld device with a radiofrequency-needle array for use in transdermal delivery of biologic drug-products via a system-specific skin patch. The company sells its products to dermatologists, plastic and cosmetic surgeons, other qualified practitioners, and aestheticians and medical spas through direct sales force and distributors; and to home-use consumers directly, as well as through retailers and a chain of distributors. Syneron Medical Ltd. was founded in 2000 and is headquartered in Yokneam Illit, Israel.

syneron medical ltd (ELOS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

syneron medical ltd (ELOS) Key Developments

Syneron Medical Ltd. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Announces Impairment Charges for the Fourth Quarter Ended December 31, 2014

Syneron Medical Ltd. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company's revenues were $74,062,000 compared to $64,282,000 a year ago. Fourth quarter 2014 revenue was negatively impacted by $1.6 million as a result of changes in foreign currency exchange rates, primarily due to the devaluation of the Euro and Japanese Yen against the U.S. dollar as compared to the fourth quarter 2013. Operating loss was $167,000 compared to operating income of $2,243,000 a year ago. Loss before tax benefit was $483,000 compared to income before tax benefit of $2,567,000 a year ago. Loss attributable to the company shareholders was $1,369,000 compared to profit attributable to the company shareholders of $9,714,000 a year ago. Basic and diluted net loss attributable to the company shareholders was $0.04 compared to profit of $0.27 a year ago. Non-GAAP operating income was $5,202,000 compared to $1,445,000 a year ago. This reflects improved operating leverage from the company's strategic investments in sales and marketing expenses related to the significant expansion of the company's North American sales force, including the establishment of a dedicated body shaping team. Non-GAAP net income attributable to the company shareholders was $3,190,000 compared to $3,983,000 a year ago. Diluted non-GAAP net income per share attributable to the company shareholders was $0.09 compared to $0.11 a year ago. Revenue growth was driven by strong execution and strategic investment in North America. Cash flow was $13.3 million in the quarter driven by revenue growth and margin expansion. For the year, the company's revenues were $255,750,000 compared to $256,915,000 a year ago. Operating loss was $2,217,000 compared to $6,119,000 a year ago. Loss before tax benefit was $2,905,000 compared to $6,093,000 a year ago. Loss attributable to the company shareholders was $5,200,000 compared to profit attributable to the company shareholders of $1,647,000 a year ago. Basic and diluted net loss attributable to the company shareholders was $0.14 compared to profit of $0.04 a year ago. Non-GAAP operating income was $12,875,000 compared to $5,491,000 a year ago. Non-GAAP net income attributable to the company shareholders was $7,944,000 compared to $6,826,000 a year ago. Diluted non-GAAP net income per share attributable to the company shareholders was $0.22 compared to $0.19 a year ago. Net cash provided by operating activities was $17,646,000 compared to net cash used in operating activities of $21,952,000 a year ago. Purchases of property and equipment were $2,803,000 compared to $3,661,000 a year ago. The company announced impairment of intangible assets of $2.0 million for the fourth quarter of 2014.

Syneron Medical Ltd. Announces Executive Appointments

Syneron Medical Ltd. announced that appointment of William Griffing as a Chief Executive Officer of Syneron Candela North America, effective immediately. In this position, Mr. Griffing will be responsible for aligning and managing the company's growth strategies for its North American business will report directly to him and to the relevant corporate managers. Mr. Griffing will also be part of Syneron's global management team. Prior to joining Syneron, Mr. Griffing served as Vice President and General Manager of Bayer Healthcare's U.S. Dermatology business. Before his time at Bayer, Mr. Griffing spent more than 20 years at Merck & Co. in various sales and marketing leadership positions, most recently as a General Manager in their Global Human Health business. The company will have three distinct Divisions in North America, including the Aesthetic Division, Body Division, and CoolTouch Division, with separate sales organizations that will focus on these specific areas of the market. The following executives will lead these Divisions and report directly to Mr. Griffing: Erik Dowell will continue in his role as President of North America leading the Company's North American Aesthetic Division. Brian Hayes will continue in his role as Vice President, Body Division, leading the Company's North American Body Division. IIan Ben David will continue to lead the company's CoolTouch Division.

Syneron Medical Ltd. to Report Q4, 2014 Results on Feb 18, 2015

Syneron Medical Ltd. announced that they will report Q4, 2014 results at 8:30 AM, US Eastern Standard Time on Feb 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELOS:US $12.10 USD +0.25

ELOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cynosure Inc $30.12 USD -0.92
El.En. SpA €30.15 EUR -0.14
Lumenis Ltd $11.33 USD -0.46
Lutronic Corp 28,700 KRW 0.00
Zeltiq Aesthetics Inc $32.75 USD -0.67
View Industry Companies
 

Industry Analysis

ELOS

Industry Average

Valuation ELOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNERON MEDICAL LTD, please visit www.syneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.